{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T11:54:33Z","timestamp":1775562873201,"version":"3.50.1"},"reference-count":58,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T00:00:00Z","timestamp":1766448000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ijoms.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Oral and Maxillofacial Surgery"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.ijom.2025.12.007","type":"journal-article","created":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T12:22:09Z","timestamp":1767615729000},"page":"524-531","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Which monoclonal antibodies cause osteonecrosis of the jaws? An overview of the current literature excluding denosumab"],"prefix":"10.1016","volume":"55","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0358-2566","authenticated-orcid":false,"given":"A.","family":"Rao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-6023-3037","authenticated-orcid":false,"given":"H.","family":"Walker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9462-2596","authenticated-orcid":false,"given":"E.","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Tong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9058-9976","authenticated-orcid":false,"given":"M.","family":"Batstone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijom.2025.12.007_bib1","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.coms.2012.10.002","article-title":"Emerging concepts in the management and treatment of osteonecrosis of the jaw","volume":"25","author":"Ruggiero","year":"2013","journal-title":"Oral Maxillofac Surg Clin North Am"},{"key":"10.1016\/j.ijom.2025.12.007_bib2","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/S0278-2391(03)00720-1","article-title":"Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic","volume":"61","author":"Marx","year":"2003","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.ijom.2025.12.007_bib3","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.oooo.2018.11.012","article-title":"Medication-related osteonecrosis of the jaw unrelated to bisphosphonates and denosumab\u2014a review","volume":"127","author":"King","year":"2019","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"key":"10.1016\/j.ijom.2025.12.007_bib4","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1016\/j.joms.2014.04.031","article-title":"American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw\u20142014 update","volume":"72","author":"Ruggiero","year":"2014","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.ijom.2025.12.007_bib5","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1093\/annonc\/mdu544","article-title":"Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12","volume":"26","author":"Gnant","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ijom.2025.12.007_bib6","first-page":"2045","article-title":"Risk factors for osteonecrosis of the jaw in cancer patients treated with denosumab: a multicenter case\u2013control study","volume":"28","author":"Fedele","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ijom.2025.12.007_bib7","first-page":"924","article-title":"Osteonecrosis of the jaw in patients treated with denosumab or bisphosphonates: a comprehensive review","volume":"33","author":"Rachner","year":"2018","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.ijom.2025.12.007_bib8","first-page":"925","article-title":"Long-term impact of bone-modifying agents for the treatment of bone metastases: a systematic review","volume":"29","author":"Ng","year":"2021","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.ijom.2025.12.007_bib9","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/S1470-2045(19)30687-4","article-title":"Adjuvant denosumab in early breast cancer (D-CARE): an international, multicentre, randomised, controlled, phase 3 trial","volume":"21","author":"Coleman","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijom.2025.12.007_bib10","article-title":"Bisphosphonates and other bone agents for breast cancer","volume":"10","author":"O\u2019Carrigan","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ijom.2025.12.007_bib11","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1111\/clr.12556","article-title":"Denosumab and osteonecrosis of the jaw. A systematic analysis of events reported in clinical trials","volume":"27","author":"Boquete-Castro","year":"2016","journal-title":"Clin Oral Implants Res"},{"key":"10.1016\/j.ijom.2025.12.007_bib12","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/S1470-2045(18)30072-X","article-title":"Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study","volume":"19","author":"Raje","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijom.2025.12.007_bib13","first-page":"679","article-title":"Delaying skeletal-related events in a randomized phase 3 study of denosumab versus zoledronic acid in patients with advanced cancer: an analysis of data from patients with solid tumors","volume":"22","author":"Henry","year":"2014","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.ijom.2025.12.007_bib14","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.ctrv.2012.07.002","article-title":"Denosumab in patients with cancer and skeletal metastases: a systematic review and meta-analysis","volume":"39","author":"Peddi","year":"2013","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ijom.2025.12.007_bib15","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.3892\/ol.2014.1982","article-title":"Comparison of the efficacy and safety of denosumab versus bisphosphonates in breast cancer and bone metastases treatment: a meta-analysis of randomized controlled trials","volume":"7","author":"Wang","year":"2014","journal-title":"Oncol Lett"},{"key":"10.1016\/j.ijom.2025.12.007_bib16","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1002\/jbmr.1479","article-title":"Five years of denosumab exposure in women with postmenopausal osteoporosis: results from the first two years of the FREEDOM extension","volume":"27","author":"Papapoulos","year":"2012","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.ijom.2025.12.007_bib17","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S2213-8587(17)30138-9","article-title":"10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension","volume":"5","author":"Bone","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.ijom.2025.12.007_bib18","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/j.joms.2022.02.008","article-title":"American Association of Oral and Maxillofacial Surgeons\u2019 position paper on medication-related osteonecrosis of the jaws\u20142022 update","volume":"80","author":"Ruggiero","year":"2022","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.ijom.2025.12.007_bib19","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","article-title":"Romosozumab treatment in postmenopausal women with osteoporosis","volume":"375","author":"Cosman","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijom.2025.12.007_bib20","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","article-title":"Romosozumab or alendronate for fracture prevention in women with osteoporosis","volume":"377","author":"Saag","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijom.2025.12.007_bib21","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s10549-010-0866-3","article-title":"Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer","volume":"122","author":"Guarneri","year":"2010","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ijom.2025.12.007_bib22","first-page":"981","article-title":"Prophylactic dental measures and the risk of osteonecrosis of the jaw in cancer patients treated with bevacizumab and other MABs","volume":"19","author":"Van den Wyngaert","year":"2011","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.ijom.2025.12.007_bib23","first-page":"565","article-title":"Demographic and clinical features of medication-related osteonecrosis of the jaw: a systematic review","volume":"23","author":"Ramirez","year":"2019","journal-title":"Clin Oral Investig"},{"key":"10.1016\/j.ijom.2025.12.007_bib24","first-page":"383","article-title":"Osteonecrosis of the jaw related to non-antiresorptive medications: a systematic review","volume":"27","author":"Nicolatou-Galitis","year":"2019","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.ijom.2025.12.007_bib25","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.ijom.2025.12.007_bib26","series-title":"Systematic reviews in the social sciences: a practical guide","author":"Petticrew","year":"2008"},{"key":"10.1016\/j.ijom.2025.12.007_bib27","series-title":"Joanna Briggs Institute Reviewer\u2019s Manual","first-page":"5","article-title":"Chapter 7: Systematic reviews of etiology and risk","author":"Moola","year":"2017"},{"key":"10.1016\/j.ijom.2025.12.007_bib28","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.jcms.2013.05.014","article-title":"Association of osteonecrosis of the jaws and POEMS syndrome in a patient assuming rituximab","volume":"42","author":"Allegra","year":"2014","journal-title":"J Craniomaxillofac Surg"},{"key":"10.1016\/j.ijom.2025.12.007_bib29","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2012-007284","article-title":"Bevacizumab-related osteonecrosis of the mandible is a self-limiting disease process","volume":"2012","author":"Bettini","year":"2012","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.ijom.2025.12.007_bib30","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.ijom.2019.08.007","article-title":"Osteonecrosis of the jaw in patients with inflammatory bowel disease treated with tumour necrosis factor alpha inhibitors","volume":"49","author":"Brijs","year":"2020","journal-title":"Int J Oral Maxillofac Surg"},{"key":"10.1016\/j.ijom.2025.12.007_bib31","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1177\/039463201202500328","article-title":"Osteonecrosis of the jaws and bevacizumab therapy: a case report","volume":"25","author":"Binello","year":"2012","journal-title":"Int J Immunopathol Pharmacol"},{"key":"10.1016\/j.ijom.2025.12.007_bib32","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.jormas.2020.05.001","article-title":"Medication-related osteonecrosis of the jaw related to epacadostat and pembrolizumab","volume":"121","author":"Decaux","year":"2020","journal-title":"J Stomatol Oral Maxillofac Surg"},{"key":"10.1016\/j.ijom.2025.12.007_bib33","doi-asserted-by":"crossref","first-page":"e2","DOI":"10.1016\/j.oraloncology.2011.07.030","article-title":"A case report of bevacizumab-related osteonecrosis of the jaw: old problem, new culprit","volume":"48","author":"Disel","year":"2012","journal-title":"Oral Oncol"},{"key":"10.1016\/j.ijom.2025.12.007_bib34","doi-asserted-by":"crossref","first-page":"4037","DOI":"10.1200\/JCO.2007.15.5424","article-title":"Osteonecrosis of the jaw related to bevacizumab","volume":"26","author":"Estilo","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijom.2025.12.007_bib35","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.12659\/AJCR.905355","article-title":"A case of osteonecrosis of the jaw in a patient with Crohn\u2019s disease treated with infliximab","volume":"18","author":"Favia","year":"2017","journal-title":"Am J Case Rep"},{"key":"10.1016\/j.ijom.2025.12.007_bib36","doi-asserted-by":"crossref","first-page":"e149","DOI":"10.1016\/j.oooo.2023.05.017","article-title":"Case report: golimumab-related osteonecrosis of the jaw","volume":"136","author":"Ghosh","year":"2023","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"key":"10.1016\/j.ijom.2025.12.007_bib37","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1093\/annonc\/mdn653","article-title":"Bevacizumab-associated osteonecrosis of the jaw","volume":"19","author":"Greuter","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ijom.2025.12.007_bib38","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1002\/ccr3.3418","article-title":"New-generation anticancer drugs and medication-related osteonecrosis of the jaw (MRONJ): late onset 3 years after ipilimumab endovenous administration with a possible role of target therapy","volume":"9","author":"Guida","year":"2021","journal-title":"Clin Case Rep"},{"key":"10.1016\/j.ijom.2025.12.007_bib39","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.joms.2011.02.104","article-title":"Osteonecrosis after administration of intravitreous bevacizumab","volume":"70","author":"Hopp","year":"2012","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.ijom.2025.12.007_bib40","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1016\/j.joms.2017.05.016","article-title":"Osteonecrosis of the jaw in a patient presenting with post-transplantation lymphoproliferative disorder treated with rituximab: a case report","volume":"75","author":"Keribin","year":"2017","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.ijom.2025.12.007_bib41","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1111\/scd.13035","article-title":"Mandibular fracture in medication-associated osteonecrosis following infliximab therapy: a case report","volume":"44","author":"Kolodziejwski","year":"2024","journal-title":"Spec Care Dentist"},{"key":"10.1016\/j.ijom.2025.12.007_bib42","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.joms.2012.03.022","article-title":"Unusual bevacizumab-related complication of an oral infection","volume":"71","author":"Magremanne","year":"2013","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.ijom.2025.12.007_bib43","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1111\/adj.12723","article-title":"Osteonecrosis of the jaw in an anti-resorptive naive patient taking trastuzumab and pertuzumab: case report","volume":"65","author":"Manzie","year":"2020","journal-title":"Aust Dent J"},{"key":"10.1016\/j.ijom.2025.12.007_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.jormas.2024.101985","article-title":"Guselkumab: a new etiological factor of medication related osteonecrosis of the jaw (MRONJ)? A case report","volume":"125","author":"Marotta","year":"2024","journal-title":"J Stomatol Oral Maxillofac Surg"},{"key":"10.1016\/j.ijom.2025.12.007_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.oraloncology.2024.106825","article-title":"Medication-related osteonecrosis of the jaws in a patient treated with pembrolizumab: report of a case and review of the literature","volume":"153","author":"Nisi","year":"2024","journal-title":"Oral Oncol"},{"key":"10.1016\/j.ijom.2025.12.007_bib46","doi-asserted-by":"crossref","first-page":"e100","DOI":"10.1016\/j.oraloncology.2015.08.014","article-title":"Osteonecrosis of the jaw: a new complication related to ipilimumab","volume":"51","author":"Owosho","year":"2015","journal-title":"Oral Oncol"},{"key":"10.1016\/j.ijom.2025.12.007_bib47","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1016\/j.ijom.2020.05.017","article-title":"Medication-related osteonecrosis of the jaws associated with intravitreal administration of ranibizumab","volume":"49","author":"Oz","year":"2020","journal-title":"Int J Oral Maxillofac Surg"},{"key":"10.1016\/j.ijom.2025.12.007_bib48","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s10006-012-0379-9","article-title":"Osteonecrosis of the mandible due to anti-angiogenic agent, bevacizumab","volume":"17","author":"Pakosch","year":"2013","journal-title":"Oral Maxillofac Surg"},{"key":"10.1016\/j.ijom.2025.12.007_bib49","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.bjoms.2023.08.241","article-title":"Pembrolizumab related osteonecrosis of the jaw","volume":"61","author":"Patel","year":"2023","journal-title":"Br J Oral Maxillofac Surg"},{"key":"10.1016\/j.ijom.2025.12.007_bib50","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.1016\/j.oooo.2022.12.013","article-title":"Osteonecrosis of the jaw associated with pembrolizumab","volume":"136","author":"Pennings","year":"2023","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"key":"10.1016\/j.ijom.2025.12.007_bib51","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.2217\/imt-2020-0108","article-title":"Osteonecrosis of the jaw induced by treatment with anti-PD-1 immunotherapy: a case report","volume":"12","author":"Pundole","year":"2020","journal-title":"Immunotherapy"},{"key":"10.1016\/j.ijom.2025.12.007_bib52","doi-asserted-by":"crossref","first-page":"e454","DOI":"10.1097\/SCS.0000000000010184","article-title":"Maxillary bone necrosis in post-COVID-19 patients: possibility of medication-related osteonecrosis of jaws (MRONJ) induced by tocilizumab","volume":"35","author":"Roh","year":"2024","journal-title":"J Craniofac Surg"},{"key":"10.1016\/j.ijom.2025.12.007_bib53","doi-asserted-by":"crossref","first-page":"e32","DOI":"10.1016\/j.oooo.2013.02.001","article-title":"Osteonecrosis of the mandible associated with bevacizumab therapy","volume":"115","author":"Santos-Silva","year":"2013","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"key":"10.1016\/j.ijom.2025.12.007_bib54","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1177\/039463200902200429","article-title":"Bevacizumab-related osteonecrosis of the jaw","volume":"22","author":"Serra","year":"2009","journal-title":"Int J Immunopathol Pharmacol"},{"key":"10.1016\/j.ijom.2025.12.007_bib55","doi-asserted-by":"crossref","DOI":"10.1016\/j.oraloncology.2021.105660","article-title":"Ramucirumab-related osteonecrosis of the jaw","volume":"125","author":"Singh","year":"2022","journal-title":"Oral Oncol"},{"key":"10.1016\/j.ijom.2025.12.007_bib56","article-title":"Medication-related osteonecrosis of the jaw: a case report of an unusual side effect of adalimumab","volume":"2023","author":"Sisalli","year":"2023","journal-title":"Case Rep Dent"},{"key":"10.1016\/j.ijom.2025.12.007_bib57","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1563\/aaid-joi-D-21-00155","article-title":"Bevacizumab-associated implant presence-triggered osteonecrosis: a case report and literature review","volume":"48","author":"Ueda","year":"2022","journal-title":"J Oral Implantol"},{"key":"10.1016\/j.ijom.2025.12.007_bib58","doi-asserted-by":"crossref","DOI":"10.1016\/j.omsc.2023.100318","article-title":"Romosozumab-associated medication-related osteonecrosis of the jaw","volume":"9","author":"Palla","year":"2023","journal-title":"Oral Maxillofac Surg Cases"}],"container-title":["International Journal of Oral and Maxillofacial Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0901502725015310?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0901502725015310?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T11:08:05Z","timestamp":1775560085000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0901502725015310"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":58,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S0901502725015310"],"URL":"https:\/\/doi.org\/10.1016\/j.ijom.2025.12.007","relation":{},"ISSN":["0901-5027"],"issn-type":[{"value":"0901-5027","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Which monoclonal antibodies cause osteonecrosis of the jaws? An overview of the current literature excluding denosumab","name":"articletitle","label":"Article Title"},{"value":"International Journal of Oral and Maxillofacial Surgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijom.2025.12.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc. on behalf of International Association of Oral and Maxillofacial Surgeons.","name":"copyright","label":"Copyright"}]}}